Total Payments
$195,635
2024 Payments
$3,572
Companies
17
Transactions
55
Medicare Patients
611
Medicare Billing
$51,753
Payment Breakdown by Category
Consulting$172,606 (88.2%)
Travel$13,896 (7.1%)
Research$3,583 (1.8%)
Other$3,540 (1.8%)
Food & Beverage$2,010 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $172,606 | 16 | 88.2% |
| Travel and Lodging | $13,896 | 18 | 7.1% |
| Unspecified | $3,583 | 1 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,540 | 1 | 1.8% |
| Food and Beverage | $2,010 | 19 | 1.0% |
Payments by Type
General
$192,052
54 transactions
Research
$3,583
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BioCardia, Inc. | $124,779 | 12 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $21,280 | 5 | $0 (2018) |
| SANOFI US SERVICES INC. | $15,679 | 6 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $14,675 | 10 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $5,000 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,583 | 1 | $0 (2020) |
| IDORSIA PHARMACEUTICALS US INC | $3,540 | 1 | $0 (2024) |
| Janssen Global Services, LLC | $2,153 | 1 | $0 (2022) |
| CSL Behring | $1,510 | 8 | $0 (2018) |
| HeartFlow, Inc. | $1,500 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,572 | 2 | IDORSIA PHARMACEUTICALS US INC ($3,540) |
| 2022 | $23,374 | 14 | Janssen Pharmaceuticals, Inc ($14,675) |
| 2021 | $10,052 | 2 | BioCardia, Inc. ($10,052) |
| 2020 | $3,619 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($3,583) |
| 2019 | $45,650 | 4 | BioCardia, Inc. ($45,408) |
| 2018 | $86,168 | 28 | BioCardia, Inc. ($46,920) |
| 2017 | $23,200 | 3 | BioCardia, Inc. ($22,400) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/21/2024 | IDORSIA PHARMACEUTICALS US INC | Tryvio (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,540.00 | General |
| Category: Hypertension | ||||||
| 08/20/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $31.64 | General |
| 12/22/2022 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 11/19/2022 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $8,300.00 | General |
| 11/19/2022 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $691.95 | General |
| 11/19/2022 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $231.34 | General |
| 11/19/2022 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $63.00 | General |
| 11/19/2022 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $52.41 | General |
| 11/19/2022 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $26.50 | General |
| 11/19/2022 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $17.47 | General |
| 11/18/2022 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $149.99 | General |
| 11/18/2022 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $137.00 | General |
| 10/12/2022 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $5,005.00 | General |
| 07/30/2022 | Esperion Therapeutics, Inc. | NEXLETOL (Drug), NEXLIZET | Food and Beverage | In-kind items and services | $47.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 02/03/2022 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $2,152.67 | General |
| 01/29/2022 | HeartFlow, Inc. | FFRct (Device) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Coronary | ||||||
| 09/30/2021 | BioCardia, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,900.00 | General |
| 07/14/2021 | BioCardia, Inc. | — | Food and Beverage | Cash or cash equivalent | $151.90 | General |
| 08/31/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $3,583.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-PART PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-951 IN HEALTHY SUBJECTS | ||||||
| 02/08/2020 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Food and Beverage | In-kind items and services | $36.04 | General |
| Category: NEUROLOGY | ||||||
| 11/15/2019 | BioCardia, Inc. | — | Consulting Fee | Cash or cash equivalent | $45,000.00 | General |
| 11/10/2019 | BioCardia, Inc. | — | Food and Beverage | Cash or cash equivalent | $407.59 | General |
| 07/07/2019 | Medtronic Vascular, Inc. | Resolute (Device) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Stents | ||||||
| 06/27/2019 | Cardiovascular Systems Inc. | Peripheral Orbital Atherectomy System (Device), Coronary Orbital Atherectomy System | Food and Beverage | Cash or cash equivalent | $117.65 | General |
| Category: Atherectomy Device | ||||||
| 11/10/2018 | BioCardia, Inc. | CardiAMP (Biological) | Food and Beverage | Cash or cash equivalent | $130.79 | General |
| Category: heart failure | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-PART PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-951 IN HEALTHY SUBJECTS | Takeda Pharmaceuticals U.S.A., Inc. | $3,583 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 131 | 178 | $61,573 | $10,655 |
| 2022 | 2 | 151 | 210 | $71,120 | $12,869 |
| 2021 | 2 | 164 | 242 | $76,180 | $16,225 |
| 2020 | 3 | 165 | 211 | $61,949 | $12,004 |
Total Patients
611
Total Services
841
Medicare Billing
$51,753
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 79 | 125 | $57,340 | $10,159 | 17.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 52 | 53 | $4,233 | $495.76 | 11.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 94 | 144 | $65,850 | $12,226 | 18.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 57 | 66 | $5,270 | $642.64 | 12.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 97 | 165 | $69,580 | $15,406 | 22.1% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 67 | 77 | $6,600 | $819.84 | 12.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 94 | 133 | $49,916 | $9,880 | 19.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 12 | $6,013 | $1,282 | 21.3% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 60 | 66 | $6,020 | $842.88 | 14.0% |
About Dr. Carl Pepine, MD
Dr. Carl Pepine, MD is a Cardiovascular Disease healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033124789.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carl Pepine, MD has received a total of $195,635 in payments from pharmaceutical and medical device companies, with $3,572 received in 2024. These payments were reported across 55 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($172,606).
As a Medicare-enrolled provider, Pepine has provided services to 611 Medicare beneficiaries, totaling 841 services with total Medicare billing of $51,753. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Gainesville, FL
- Active Since 07/30/2006
- Last Updated 03/06/2008
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1033124789
Products in Payments
- CardiAMP (Biological) $46,920
- CardiAMP System (Device) $22,400
- ILARIS (Biological) $21,280
- NO PRODUCT DISCUSSED (Drug) $15,858
- Tryvio (Drug) $3,540
- FFRct (Device) $1,500
- IW-1973 $800.00
- Resolute (Device) $124.99
- Peripheral Orbital Atherectomy System (Device) $117.65
- NEXLETOL (Drug) $47.00
- TEGSEDI (Drug) $36.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Gainesville
Dr. Juan Aranda, Md, MD
Cardiovascular Disease — Payments: $357,500
Cardiovascular Disease $357,500
Mudassar Ahmed, Mbbs, MBBS
Cardiovascular Disease — Payments: $337,874
Cardiovascular Disease $337,874
Dr. Matheen Khuddus, M.d, M.D
Cardiovascular Disease — Payments: $223,657
Cardiovascular Disease $223,657
Dr. Ann Tong, Md, MD
Cardiovascular Disease — Payments: $198,583
Cardiovascular Disease $198,583
Dr. Michael Koren, M.d, M.D
Cardiovascular Disease — Payments: $193,105
Cardiovascular Disease $193,105
Keith March, M.d, M.D
Cardiovascular Disease — Payments: $176,239
Cardiovascular Disease $176,239